Bluebird Sickle Cell Gene Therapy Hangs In Balance
Company Probes Causes Of Blood Cancers
Executive Summary
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
You may also be interested in...
Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort
The company will prioritize US market for gene therapies; FDA also placed eli-cel for CALD on clinical hold following a case of MDS.
GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
Bluebird Lenti-D Data Give Gene Therapy Business Another Boost
The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.